Trajan Wealth LLC Grows Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Trajan Wealth LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 204,966 shares of the company's stock after purchasing an additional 19,797 shares during the period. Trajan Wealth LLC's holdings in Kenvue were worth $4,376,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Bard Financial Services Inc. boosted its stake in Kenvue by 5.7% during the 3rd quarter. Bard Financial Services Inc. now owns 106,790 shares of the company's stock worth $2,470,000 after acquiring an additional 5,750 shares during the last quarter. Boyar Asset Management Inc. raised its stake in Kenvue by 7.2% during the 3rd quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company's stock worth $675,000 after buying an additional 1,948 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Kenvue in the third quarter valued at about $1,057,000. Tidal Investments LLC increased its holdings in shares of Kenvue by 9.9% in the third quarter. Tidal Investments LLC now owns 131,128 shares of the company's stock worth $3,033,000 after acquiring an additional 11,849 shares in the last quarter. Finally, Oddo BHF Asset Management Sas bought a new position in shares of Kenvue during the 3rd quarter valued at about $1,570,000. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KVUE. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group cut their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Finally, Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Kenvue has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Stock Down 1.0 %

NYSE KVUE traded down $0.24 during mid-day trading on Wednesday, hitting $22.95. The company's stock had a trading volume of 13,014,749 shares, compared to its average volume of 17,110,213. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company's 50 day simple moving average is $22.97 and its 200 day simple moving average is $22.41. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The firm has a market capitalization of $44.03 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.57%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.